Medicare utilization — HENNA MUKHTAR MALIK (M.D.)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21,420 | 32 | $0 | $8,389 |
| J1756 | Injection, iron sucrose, 1 mg | 7,600 | 15 | $0 | $1,190 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,020 | 16 | $0 | $14,111 |
| J9271 | Injection, pembrolizumab, 1 mg | 5,200 | 12 | $0 | $224,640 |
| J0897 | Injection, denosumab, 1 mg | 2,580 | 16 | $0 | $47,332 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·